CoChat

Molecular Signature for Receptor Engagement in the Metabolic Peptide Hormone Amylin

Open access
Bower, Rebekah L., Yule, Lauren, Rees, Tayla A., Deganutti, Giuseppe, Hendrikse, Erica R., Harris, Paul W. R., Kowalczyk, Renata, Ridgway, Zachary, Wong, Amy G., Swierkula, Katarzyna, Raleigh, Daniel P., Pioszak, Augen A., Brimble, Margaret A., Reynolds, Christopher A., Walker, Christopher S., Hay, Debbie L. · 2018 · ACS Pharmacology & Translational Science
Cited by 80

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

The pancreatic peptide hormone, amylin, plays a critical role in the control of appetite, and synergizes with other key metabolic hormones such as glucagon-like peptide 1 (GLP-1). There is opportunity to develop potent and long-acting analogues of amylin or hybrids between these and GLP-1 mimetics for treating obesity. To achieve this, interrogation of how the 37 amino acid amylin peptide engages with its complex receptor system is required. We synthesized an extensive library of peptides to profile the human amylin sequence, determining the role of its disulfide loop, amidated C -terminus and receptor “capture” and “activation” regions in receptor signaling. We profiled four signaling pathways with different ligands at multiple receptor subtypes, in addition to exploring selectivity determinants between related receptors. Distinct roles for peptide subregions in receptor binding and activation were identified, resulting in peptides with greater activity than the native sequence. Enhanced peptide activity was preserved in the brainstem, the major biological target for amylin. Interpretation of our data using full-length active receptor models supported by molecular dynamics, metadynamics, and supervised molecular dynamics simulations guided the synthesis of a potent dual agonist of GLP-1 and amylin receptors. The data offer new insights into the function of peptide amidation, how allostery drives peptide–receptor interactions, and provide a valuable resource for the development of novel amylin agonists for treating diabetes and obesity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acsptsci.8b00002

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 80

Metadata

Authors
Bower, R. L., Yule, L., Rees, T. A., Deganutti, G., Hendrikse, E. R., Harris, P. W. R., Kowalczyk, R., Ridgway, Z., Wong, A. G., Swierkula, K., Raleigh, D. P., Pioszak, A. A., Brimble, M. A., Reynolds, C. A., Walker, C. S., & Hay, D. L.
Venue
ACS Pharmacology & Translational Science
Published
2018-04-23
Volume
1
Issue
1
Pages
32-49
ISSN
2575-9108 (ISSN-L)
OpenAlex
W2802743042
Cited by
80
References
15
FWCI
2.43
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular Signature for Receptor Engagement in the Metabolic Peptide Hormone Amylin. https://app.cochat.ai/papers/10.1021/acsptsci.8b00002
The paper
Bower, R. L., Yule, L., Rees, T. A., Deganutti, G., Hendrikse, E. R., Harris, P. W. R., Kowalczyk, R., Ridgway, Z., Wong, A. G., Swierkula, K., Raleigh, D. P., Pioszak, A. A., Brimble, M. A., Reynolds, C. A., Walker, C. S., & Hay, D. L. (2018). Molecular Signature for Receptor Engagement in the Metabolic Peptide Hormone Amylin. ACS Pharmacology & Translational Science. https://doi.org/10.1021/acsptsci.8b00002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.